China News Service, Beijing, September 27 (Reporter Du Yan) The 24th National Conference on Clinical Oncology and the 2021 Chinese Society of Clinical Oncology (CSCO) Academic Annual Meeting opened in Beijing.

Today, the reporter learned from the organizing committee that the theme of this conference is "Focus on Innovative Research, Leading the Original Future", focusing on promoting academic exchanges and scientific and technological cooperation in the field of clinical oncology in China, encouraging and supporting clinical research and innovation, and advocating multidisciplinary standardization Precision oncology based on comprehensive treatment actively promotes the development of the discipline.

　　With the solidarity and cooperation and unremitting exploration of Chinese clinical oncologists, CSCO's influence in the international oncology community continues to increase.

At the opening ceremony of this annual meeting, the presidents of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) both sent video speeches to congratulate the successful opening of the CSCO annual meeting.

　　ASCO Chairman Everett Vokes said in his speech that he admires the unremitting efforts of Chinese colleagues in academic fields. The two societies of CSCO and ASCO have maintained cooperation and friendship for many years. In the past year and a half, it has been extremely difficult for everyone. At the same time It also reminds us of the importance of relying on each other and international cooperation, "Only by working together and learning from each other can we seek more benefits for patients. Only by breaking the national boundaries can we truly improve the quality of life of patients."

　　ESMO Chairman Solange Peters pointed out in his speech that CSCO will hold its annual meeting as scheduled under the new crown pneumonia epidemic, which allows oncologists around the world to continue to maintain close contact and cooperation, and to maintain the pace of research for the benefit of all patients. Global cooperation is essential for solving the problem. The burden of cancer is crucial.

ESMO is honored and proud to cooperate with CSCO, which has adhered to this principle for a long time, and looks forward to maintaining long-term cooperation with CSCO in the future.

　　CSCO old friend, CSCO steering committee member, and co-founder of the American Society of Translational Medicine Martin J. Murphy also congratulated the convening of the conference.

Over the past 43 years, Murphy has witnessed many changes in China during a total of 125 work trips to China.

Murphy hopes that everyone will work together to create hope and history for cancer patients in China and around the world.

　　He Jie, Chairman of the CSCO Council, reviewed the two years of the CSCO Council at the opening, and hoped that colleagues will work together and cooperate sincerely in future work to achieve a new peak in the development of the Chinese Society of Clinical Oncology.

　　Academician Shao Feng of the Chinese Academy of Sciences and the Beijing Institute of Biological Sciences published a report entitled "Cell Pyrolysis and Tumor Immunity", introducing a method of cellular immune death related to oncology-Cell Pyrolysis.

Academician Zhang Xuemin of the Academy of Military Sciences delivered a speech titled "Research on the Development Strategy of Cell Medicine", explaining from multiple dimensions the argument that "all the problems of life must be found in cells to find answers" and analyzed cell biology to promote the development of modern medicine. The underlying logic of human beings, and by enumerating the three stages of human understanding of tumors.

Academician Yu Jinming of Shandong Cancer Hospital and the guests discussed issues related to the new practice of precision oncology.

　　In the keynote speech of the conference, the chairman of the conference, Professor Li Jin of Shanghai Oriental Hospital affiliated to Tongji University, the secretary-general of the conference, vice chairman of CSCO, and professor of PLA General Hospital Professor Jiang Zefei, Professor Qin Shukui of Eastern Theater Command General Hospital, and Zhou Caicun of Shanghai Pulmonary Hospital Affiliated to Tongji University The professors all shared the latest research results in their respective fields.

　　At the opening ceremony, CSCO Annual Achievement Award and Outstanding Paper Award were presented.

The winner of the 2021 CSCO Annual Meeting Annual Achievement Award is Professor Wu Yilong from Guangdong Provincial People’s Hospital. He led 230 teams from 26 countries and regions around the world to use the third-generation targeted drug osimertinib for lung cancer. Postoperative adjuvant treatment has reduced the risk of lung cancer recurrence or death by 83%, rewritten the global model of only adjuvant chemotherapy after lung cancer surgery for more than 20 years, and has benefited tens of millions of lung cancer patients and their families.

The ADAURA study published in NEJM is an example of precision medicine for early-stage lung cancer patients, and established that recurrence-free and metastasis-free survival can be used as an end-point indicator for approved lung cancer indications, blazing a new trail for pan-cancer clinical research.

　　According to reports, the annual meeting selected 10 blockbuster studies from 1,470 submitted papers, 120 headnote reports, and 105 submissions for innovative research. As the excellent papers of this conference, Professor Xu Ruihua announced the award results on the spot.

　　The annual meeting will last until September 29, with 68 special sessions, attracting more than 12,000 registered representatives and hundreds of experts to share the latest academic progress and exchange cutting-edge diagnosis and treatment concepts.

(over)